Publication at Faculty of Medicine in Hradec Králové |
2014
Abstract
Insulin degludec is a new basal insulin analogue with very long effect, longer than 42 hours. Having reached a stable plasma level , its effect is steady, without any undesirable fluctuations.
The dosage is flexible, and has been shown to have excellent effect on both type 1 and type 2 diabetes control. Hypoglycaemia risk is lower than that associated with classic insulins.
The new insulin may thus help singnificantly not only to increase the effectiveness of diabetes treatment but also treatment safety and patient comfort.
